282 related articles for article (PubMed ID: 16369892)
1. Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss.
Mizunuma H; Shiraki M; Shintani M; Gorai I; Makita K; Itoga S; Mochizuki Y; Mogi H; Iwaoki Y; Kosha S; Yasui T; Ishihara O; Kurabayashi T; Kasuga Y; Hayashi K
J Bone Miner Metab; 2006; 24(1):11-5. PubMed ID: 16369892
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.
Gutteridge DH; Holzherr ML; Retallack RW; Price RI; Will RK; Dhaliwal SS; Faulkner DL; Stewart GO; Stuckey BG; Prince RL; Criddle RA; Drury PJ; Tran L; Bhagat CI; Kent GN; Jamrozik K
Calcif Tissue Int; 2003 Jul; 73(1):33-43. PubMed ID: 14506952
[TBL] [Abstract][Full Text] [Related]
3. Additive effect of alfacalcidol on bone mineral density of the lumbar spine in Taiwanese postmenopausal women treated with hormone replacement therapy and calcium supplementation: a randomized 2-year study.
Chen M; Chow SN
Clin Endocrinol (Oxf); 2001 Aug; 55(2):253-8. PubMed ID: 11531934
[TBL] [Abstract][Full Text] [Related]
4. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
5. Prevention of postmenopausal bone loss with exchange for short-term HRT for 1alpha-hydroxycholecalciferol.
Ushiroyama T; Ikeda A; Sakai M; Higashiyama T; Ueki M
Maturitas; 2003 Jun; 45(2):119-27. PubMed ID: 12787970
[TBL] [Abstract][Full Text] [Related]
6. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3.
Gorai I; Chaki O; Taguchi Y; Nakayama M; Osada H; Suzuki N; Katagiri N; Misu Y; Minaguchi H
Calcif Tissue Int; 1999 Jul; 65(1):16-22. PubMed ID: 10369728
[TBL] [Abstract][Full Text] [Related]
7. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial.
Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Alhava E; Honkanen R; Jurvelin J; Saarikoski S
J Clin Endocrinol Metab; 1999 Feb; 84(2):546-52. PubMed ID: 10022414
[TBL] [Abstract][Full Text] [Related]
8. Effects on bone of oral hormone replacement therapy initiated 2 years after ovariectomy in young adult monkeys.
Jayo MJ; Register TC; Carlson CS
Bone; 1998 Oct; 23(4):361-6. PubMed ID: 9763148
[TBL] [Abstract][Full Text] [Related]
9. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
10. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
Tuppurainen MT; Komulainen M; Kröger H; Honkanen R; Jurvelin J; Puntila E; Heikkinen AM; Alhava E; Saarikoski S
Osteoporos Int; 1998; 8(1):32-8. PubMed ID: 9692075
[TBL] [Abstract][Full Text] [Related]
11. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
12. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
Osteoporos Int; 2005 Apr; 16(4):372-9. PubMed ID: 15654581
[TBL] [Abstract][Full Text] [Related]
13. Association of transforming growth factor beta1 genotype with therapeutic response to active vitamin D for postmenopausal osteoporosis.
Yamada Y; Harada A; Hosoi T; Miyauchi A; Ikeda K; Ohta H; Shiraki M
J Bone Miner Res; 2000 Mar; 15(3):415-20. PubMed ID: 10750555
[TBL] [Abstract][Full Text] [Related]
14. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
[TBL] [Abstract][Full Text] [Related]
15. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study.
Mizunuma H; Okano H; Soda M; Kagami I; Miyamoto S; Tokizawa T; Honjo S; Ibuki Y
Maturitas; 1997 May; 27(1):69-76. PubMed ID: 9158080
[TBL] [Abstract][Full Text] [Related]
16. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
[TBL] [Abstract][Full Text] [Related]
17. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial.
Villareal DT; Binder EF; Williams DB; Schechtman KB; Yarasheski KE; Kohrt WM
JAMA; 2001 Aug; 286(7):815-20. PubMed ID: 11497535
[TBL] [Abstract][Full Text] [Related]
19. Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women.
Meschia M; Brincat M; Barbacini P; Maini MC; Marri R; Crosignani PG
Eur J Obstet Gynecol Reprod Biol; 1992 Oct; 47(1):53-7. PubMed ID: 1330761
[TBL] [Abstract][Full Text] [Related]
20. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Manguso F; Nunziata V; Mastrantonio P; Lombardi G; Zullo F
Osteoporos Int; 2005 Aug; 16(8):943-52. PubMed ID: 15739035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
